Salivary gland cancer clinical trials

Seattle Cancer Care Alliance (SCCA) was formed, in part, to bring promising new treatments to patients faster. For salivary gland cancer patients, this means more treatment options at SCCA than you might find elsewhere, including the chance to participate in one of many ongoing clinical trials conducted at SCCA and its partner organizations, Fred Hutch and UW Medicine.

  • Below is a list of salivary gland cancer clinical trials that are currently open and accepting patients at SCCA.
  • For general information about clinical trials, see the Patient Guide to Clinical Trials.

Displaying 6 of 6 trials.

Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
A Randomized Phase II / Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
View Trial
Investigator:
Cristina Rodriguez
Study ID:
NCT01220583
Dose Escalation and Expansion of JTX-2011 Alone or in Combination With Anti-PD-1 in Subjects With Advanced Solid Tumors (ICONIC)

A Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects with Advanced Refractory Solid Tumor Malignancies

View Trial
Investigator:
Scott S. Tykodi
Study ID:
NCT02904226
Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)
A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors
View Trial
Investigator:
Christina S. Baik
Study ID:
NCT02576431
A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors
A Phase 1 Study of SL-801, a Reversible Inhibitor of Nuclear Export, in Patients with Advanced Solid Tumors
View Trial
Investigator:
Gabriela Chiorean
Study ID:
NCT02667873
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)
An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
View Trial
Investigator:
Gabriela Chiorean
Study ID:
NCT02568267
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
View Trial
Investigator:
Heidi J. Gray
Study ID:
NCT02834013